The ear wax could offer clues of Parkinson’s early disease, the study suggests

The ear wax can provide an unexpected early warning of Parkinson’s disease (EP), according to new research.

In particular, their smell could help doctors detect progressive neurological movement disorder, the researchers said in the study, which was published in the analytical magazine Chemistry.

Parkinson is generally diagnosed after an individual demonstrates symptoms such as tremors, stiffness, bradykinesia (slow movement) and gear changes, according to health experts.

Parkinson’s patients take ‘magical fungi’ see the key benefits, the study finds

The study suggested that volatile organic compounds (COV), which are released by sebum (oily secretions that help lubricate and protect the skin) in the ear of people with Parkinson’s ear, have a certain distinctive smell.

The smell is the result of systemic inflammation, neurodegeneration and oxidative stress related to the progression of the disease, as noted in the report of the American Chemical Society.

“There is evidence that Parkinson’s disease patients produce excess sebum, and other research groups have shown that there are particular chemical profiles of this sebum compared to patients without EP”, Dr. Joohi Jiménez-Shahed, medical director of movement disorders, neuromodulation and therapeutic of the cerebral circuit at the ICAHN Medicine School in Mount Sinai in New York City, said News Digital.

(Jiménez-Shahed was not affiliated with the study).

Stem cell therapy for Parkinson ‘strong promise’ shows to relieve symptoms

In this recent study, China’s researchers analyzed Wax swollen from the ear channels of 209 participants, 108 of which had been diagnosed with Parkinson’s.

Using specialized methods to analyze chemicals in the wax, the researchers found that four of the voc in people with the disease were significantly different from those who had not been diagnosed, the study detailed.

They concluded that four voc (ethylbenzene, 4-ethyltoluene, pentanal and 2-pentadecil-1,3-dioxolano)) can serve as potential biomarkers for EP.

The researchers used the wax data collected to train an olfactory system of artificial intelligence (AIO), technology that uses sensors to simulate the meaning of human smell to detect and analyze voc.

The new medication for Parkinson has proven effective in clinical trials: ‘Very encouraged’

According to the report, the AIO system showed 94% accuracy with wax samples for the ear of people with and without Parkinson.

The authors of the study suggested that the AIO system could eventually be used as a first -line detection tool for Parkinson’s early detection, allowing an earlier treatment of the disease.

Most current treatments only handle symptoms and help maintain the quality of life, but do not stop or reinvote the disease, which makes vital diagnosis and early treatment, according to the National Institute of Neurological Disorders and stroke (NINDS).

The report also noted that current tests for Parkinson’s, such as image studies and clinical qualification scales, can be expensive and subjective.

This potential detection system could provide an easy and economical way to test the disease, although experts indicated that more tests are needed.

Limitations and future research

The study was conducted on a small scale in a single clinic in China, according to Hao Dong, one of the authors of the study at the Frantier Fundamental Studies Research Center in China.

Click here to get the News application

“The next step is to carry out more research in different stages of the disease, in multiple research centers and among multiple ethnic groups, to determine if this method has a greater practical value of the application,” Dong said in a press release.

Jiménez-Shahed said that ideally, this new method could serve as an early diagnostic test, potentially easier than using spinal fluid, skin biopsies or specialized explorations.

Click here to register in our health newsletter

The previous expert, who is also an associate professor of neurology and neurosurgery at the ICAHN School of Medicine in Mount Sinai, warned that the particular profiles of the Ear Wax COV informed in the recent study may differ from the findings of other studies.

“There must be replication and/or expansion of the sample size before determining the specific diagnostic potential of a test like this,” he added.

Those who are concerned about Parkinson’s potential risk should consult with a neurologist or movement disorder specialist, Jiménez-Shahed advised.

A specialist can carefully detect the individual for early warning signals and determine the need for additional diagnostic tests or treatment treatment.

For more health articles, visit www.Newsnews.com/health

The study was funded by the National Foundation of Natural Sciences of Science, the Pioneer and the R&D program of Goose leader of the province of Zhejiang, and the fundamental research funds for the central universities.

News Digital contacted the study authors to make more comments.